Sign in to view content

Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2022

Related

Association Between Early Vision-Related Quality of Life (QoL) Outcomes and Anatomic Dryness in neovascular AMD and DME in the VIEW and FAME trials
Michael A. Singer, MD
On Demand Cases, Courses, and Papers
2019
Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2023
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion: 72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Annual Meeting Talks
2024

Category: AMD-Neovascular

See more